東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Advances in antiviral drug design.. ...

Clercq, E. de

FindBook

Google Book

Amazon

博客來

Advances in antiviral drug design.. Vol. 4

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Advances in antiviral drug design./ editor, E. de Clerq.{me_controlnum}
其他作者:	Clercq, E. de
出版者:	Amsterdam ;Elsevier Science, : 2003.,
面頁冊數:	1 v.
附註:	Includes index.
標題:	Antiviral agents - Design. -
電子資源:	http://www.sciencedirect.com/science/book/9780444506023
ISBN:	9780444506023

Advances in antiviral drug design.. Vol. 4
Advances in antiviral drug design.Vol. 4[electronic resource] /editor, E. de Clerq.{me_controlnum} - Amsterdam ;Elsevier Science,2003. - 1 v.

Includes index.

The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections. First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use. Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young. Third, as all currently available PIs can be described as "peptidomimetic", and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister. Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim. Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents. Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses. The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.

Electronic reproduction.
Amsterdam :
Elsevier Science & Technology,
2007.

Mode of access: World Wide Web.

ISBN: 9780444506023

Source: 123192:129010Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:

1362277
Antiviral agents
--Design.Index Terms--Genre/Form:

542853
Electronic books.

LC Class. No.: RM411 / .A38 2003

Dewey Class. No.: 615.37

Advances in antiviral drug design.. Vol. 4
LDR:04163cmm 2200313Ia 4500 001 1033056
003 OCoLC
005 20110614113925.0
006 m d
007 cr cn|||||||||
008 120420s2003 ne o 001 0 eng d
020 $a 9780444506023
020 $a 0444506020
029 1 $a NZ1 $b 12434616
035 $a (OCoLC)162131026
035 $a ocn162131026
037 $a 123192:129010 $b Elsevier Science & Technology $n http://www.sciencedirect.com
040 $a OPELS $c OPELS $d OPELS
049 $a TEFA
050 1 4 $a RM411 $b .A38 2003
082 0 4 $a 615.37 $2 22
245 0 0 $a Advances in antiviral drug design. $n Vol. 4 $h [electronic resource] / $c editor, E. de Clerq.{me_controlnum}
260 $a Amsterdam ; $a Oxford : $b Elsevier Science, $c 2003.
300 $a 1 v.
500 $a Includes index.
520 $a The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections. First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use. Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young. Third, as all currently available PIs can be described as "peptidomimetic", and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister. Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim. Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents. Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses. The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.
533 $a Electronic reproduction. $b Amsterdam : $c Elsevier Science & Technology, $d 2007. $n Mode of access: World Wide Web. $n System requirements: Web browser. $n Title from title screen (viewed on July 25, 2007). $n Access may be restricted to users at subscribing institutions.
650 0 $a Antiviral agents $x Design. $3 1362277
655 7 $a Electronic books. $2 lcsh $3 542853
700 1 $a Clercq, E. de $q (Erik) $3 1362276
710 2 $a ScienceDirect (Online service) $3 848416
776 1 $c Original $z 0444506020 $z 9780444506023 $w (OCoLC)52990590
856 4 0 $3 ScienceDirect $u http://www.sciencedirect.com/science/book/9780444506023
994 $a C0 $b TEF